<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04102605</url>
  </required_header>
  <id_info>
    <org_study_id>DB_NV_P01</org_study_id>
    <nct_id>NCT04102605</nct_id>
  </id_info>
  <brief_title>Visual Perceptual Learning for the Treatment of Visual Field Defect</brief_title>
  <acronym>VIVID2</acronym>
  <official_title>Efficacy and Safety of Visual Perceptual Learning Using the Nunap Vision for Improvement of Visual Field Defect Caused by Brain Damage: Multi Center, Superiority Prove, Double-blind, Randomized, Confirmatory Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nunaps Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nunaps Inc</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the efficacy of visual perceptual learning for the treatment of visual&#xD;
      field defect caused by brain damage. Half of participants will receive visual perceptual&#xD;
      training using the Nunap Vision, while the other half will receive sham training using the&#xD;
      Nunap Vision-C.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 17, 2019</start_date>
  <completion_date type="Actual">May 31, 2021</completion_date>
  <primary_completion_date type="Actual">May 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area of Humphrey visual field where sensitivity increased by equal or more than 6 dB relative to baseline</measure>
    <time_frame>12 weeks</time_frame>
    <description>Improved regions have luminance sensitivity that increased by equal or more than 6 dB relative to baseline. The improved area ranges between 0 and 972 degree^2, of which larger area indicates better outcome.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in Humphrey visual field mean deviation relative to baseline</measure>
    <time_frame>12 weeks</time_frame>
    <description>Changes in mean deviation value of whole field or defect field compared with the baseline value. The change of mean deviation ranges between -35 to +35 dB, of which higher value indicates better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in scores of NEI-VFQ-25(the National Eye Institute Visual Function Questionnaire 25) relative to baseline</measure>
    <time_frame>12 weeks</time_frame>
    <description>Changes in each components of NEI-VFQ-25 scores relative to baseline. The change of scores ranges between -100 to 100, of which higher value indicates better outcome.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Visual Fields Hemianopsia</condition>
  <condition>Hemianopsia, Homonymous</condition>
  <arm_group>
    <arm_group_label>Nunap Vision</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nunap Vision , 5 days a week for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nunap Vision-C</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Nunap Vision-C, 5 days a week for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Nunap Vision</intervention_name>
    <description>Participants receive visual perceptual training using the Nunap Vision software</description>
    <arm_group_label>Nunap Vision</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Nunap Vision-C</intervention_name>
    <description>Participants receive sham training using the Nunap Vision-C software</description>
    <arm_group_label>Nunap Vision-C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 19-80 years&#xD;
&#xD;
          -  Brain damage-induced visual field defect&#xD;
&#xD;
          -  At least 6 months after brain lesion&#xD;
&#xD;
          -  Minimum of 4 testing locations, where measured threshold ≤ 20dB&#xD;
&#xD;
          -  Verified visual pathway damage using CT or MRI&#xD;
&#xD;
          -  K-MMSE(Korean Mini Mental Status Examination) score ≥ 24&#xD;
&#xD;
          -  Visual acuity equal or better than 20/40&#xD;
&#xD;
          -  Able to use the investigational device&#xD;
&#xD;
          -  Patient/legally authorized representative has signed the informed consent form&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Unreliable Humphrey visual field test (any of fixation loss, false positive, false&#xD;
             negative ≥ 20%)&#xD;
&#xD;
          -  Complete hemianopsia with sensitivity of the whole hemifield ≤ 3 dB&#xD;
&#xD;
          -  Epilepsy, photosensitivity, Parkinson's disease&#xD;
&#xD;
          -  Bilateral visual field defect&#xD;
&#xD;
          -  Hemispatial neglect&#xD;
&#xD;
          -  Ophthalmologic disorder that may interfere the trial&#xD;
&#xD;
          -  Inability to discontinue psychostimulants such as methylphenidate, modafinil, and&#xD;
             amphetamine.&#xD;
&#xD;
          -  Candidate for carotid endarterectomy or stenting&#xD;
&#xD;
          -  Received ophthalmologic surgery within 3 months, except for the cataract surgery&#xD;
&#xD;
          -  Pregnant or breast feeding&#xD;
&#xD;
          -  Participating in other clinical trial&#xD;
&#xD;
          -  Any other condition that, in the opinion of the investigator, precludes participation&#xD;
             in the trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sun U. Kwon, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Asan Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Seongnam</city>
        <state>Kyunggi-do</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chung-Ang University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Konkuk University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>September 23, 2019</study_first_submitted>
  <study_first_submitted_qc>September 23, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 25, 2019</study_first_posted>
  <last_update_submitted>June 6, 2021</last_update_submitted>
  <last_update_submitted_qc>June 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Visual field defect</keyword>
  <keyword>visual perceptual learning</keyword>
  <keyword>Humphrey visual field</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemianopsia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

